期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 12, 期 10, 页码 995-1009出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2006.04.009
关键词
graft-versus-host disease; regulatory T cells (Tregs); graft-versus-tumor; immunity; engraftment
资金
- NHLBI NIH HHS [5 P01 HL075462] Funding Source: Medline
- NIAID NIH HHS [K08AI060888] Funding Source: Medline
Naturally arising CD4(+)CD25(+) regulatory T cells (Tregs) have the potential to suppress aberrant immune responses and to regulate peripheral T-cell homeostasis. In murine models of bone marrow transplantation, Tregs promote donor bone marrow engraftment and decrease the incidence and severity of graft-versus-host-disease without abrogating the beneficial graft-versus-tumor immunologic effect. These findings, in concert with observations that Tregs in mice and humans share phenotypic and functional characteristics, have led to active investigations into the use of these cells to decrease complications associated with human hematopoietic cell transplantation. Early human studies suggest that an imbalance of Tregs and effector T cells may contribute to the development of graft-versus-host-disease. However, the mechanisms of immunoregulation, in particular the allorecognition properties of Tregs, their effects on and interaction with other immune cells, and their sites of suppressive activity, are not well understood. In this review, we discuss the current knowledge of Treg biology and the potential therapeutic strategies and barriers of Treg immunotherapy in human hematopoietic cell transplantation. (C) 2006 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据